ArticleJournal of internal medicine2025
Systemic neutrophil activation and N-formyl methionine-formyl peptide receptor-1 signaling define inflammatory endotypes in rheumatoid arthritis-associated lung involvement.
Article in Journal of internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Protective Effects of Cyclosporin H Against Sepsis-Induced Acute Kidney Injury via Modulation of Fpr1 Signaling and Inhibiting Pyroptosis.Research and reports in urology · 2026Article
- Systemic neutrophil activation and N-formyl methionine-formyl peptide receptor-1 signaling define inflammatory endotypes in rheumatoid arthritis-associated lung involvement.Journal of internal medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundNeutrophil activation plays a crucial role in the pathogenesis of rheumatoid arthritis (RA), but its involvement in RA-associated interstitial lung disease (RA-ILD) remains unclear. This study investigated the involvement of N-formyl methionine (fMET) and its receptor formyl peptide receptor-1 (FPR1) in neutrophil-mediated inflammation in RA-ILD.
methodsPlasma and sputum levels of fMET and neutrophil activation markers were measured by ELISA in two cohorts (n = 269 and 314) spanning multiple disease subgroups. Neutrophil activation was assessed by flow cytometry following plasma stimulation, with or without FPR1 inhibitors.
resultsCalprotectin levels were significantly elevated in both plasma and sputum of RA-ILD patients compared to controls and RA-noILD patients (p < 0.05 for all analyses) and were negatively correlated with pulmonary function in RA (forced vital capacity [FVC], r = -0.39, p = 0.0002; diffusing capacity for carbon monoxide [DLCO], r = -0.39, p = 0.001). Plasma fMET levels were higher in RA-ILD patients compared to healthy controls (p < 0.0001) as well as compared to RA-noILD patients (p < 0.01), with a significant inverse correlation to pulmonary function in RA patients (FVC, r = -0.42, p < 0.0001; DLCO, r = -0.31, p = 0.01). Plasma from RA-ILD patients induced neutrophil activation through FPR1-dependent mechanisms (p < 0.0001). Hierarchical clustering identified reproducible subgroups defined by fMET and calprotectin, with the high-fMET cluster enriched for RA-ILD and associated with lower DLCO (p < 0.05).
conclusionsThe fMET-FPR1 axis is associated with neutrophil activation in RA-ILD and defines inflammatory endotypes associated with lung impairment. Neutrophil-based biomarkers may enable early risk stratification and provide rationale for targeting the fMET-FPR1 axis in RA-ILD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.